These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 18572756)

  • 41. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Moreno L; Quereda C; Moreno A; Perez-Elías MJ; Antela A; Casado JL; Dronda F; Mateos ML; Bárcena R; Moreno S
    AIDS; 2004 Jan; 18(1):67-73. PubMed ID: 15090831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
    Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.
    Soriano V; Maida I; Núñez M; García-Samaniego J; Barreiro P; Martín-Carbonero L; González-Lahoz J
    Antivir Ther; 2004 Dec; 9(6):987-92. PubMed ID: 15651757
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
    Ballesteros AL; Miró O; López S; Fuster D; Videla S; Martínez E; Garrabou G; Salas A; Côté H; Tor J; Rey-Joly C; Planas R; Clotet B; Tural C
    Antivir Ther; 2004 Dec; 9(6):969-77. PubMed ID: 15651755
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
    Mira JA; Neukam K; López-Cortés LF; Rivero-Juárez A; Téllez F; Girón-González JA; de los Santos-Gil I; Ojeda-Burgos G; Merino D; Ríos-Villegas MJ; Collado A; Torres-Cornejo A; Macías J; Rivero A; Pérez-Pérez M; Pineda JA; ;
    Eur J Clin Microbiol Infect Dis; 2015 Sep; 34(9):1879-84. PubMed ID: 26115631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.
    Vigani AG; Gonçales ES; Pavan MH; Genari F; Tozzo R; Lazarini MS; Fais V; Feltrin A; Gonçales NS; Gonçales FL
    Braz J Infect Dis; 2012; 16(3):232-6. PubMed ID: 22729189
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
    Harrison SA; Rossaro L; Hu KQ; Patel K; Tillmann H; Dhaliwal S; Torres DM; Koury K; Goteti VS; Noviello S; Brass CA; Albrecht JK; McHutchison JG; Sulkowski MS
    Hepatology; 2010 Sep; 52(3):864-74. PubMed ID: 20568303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.
    Aguilar Marucco D; Gonzalez de Requena D; Bonora S; Tettoni C; Bonasso M; De Blasi T; D'Avolio A; Sciandra M; Siccardi M; Baietto L; Trentini L; Sinicco A; Cariti G; Di Perri G
    J Antimicrob Chemother; 2008 Apr; 61(4):919-24. PubMed ID: 18238889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
    Laguno M; Murillas J; Blanco JL; Martínez E; Miquel R; Sánchez-Tapias JM; Bargallo X; García-Criado A; de Lazzari E; Larrousse M; León A; Loncá M; Milinkovic A; Gatell JM; Mallolas J
    AIDS; 2004 Sep; 18(13):F27-36. PubMed ID: 15316335
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
    Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
    J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
    Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy.
    de Mendoza C; Martin-Carbonero L; Barreiro P; de Baar M; Zahonero N; Rodriguez-Novoa S; Benito JM; González-Lahoz J; Soriano V
    AIDS; 2007 Mar; 21(5):583-8. PubMed ID: 17314520
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.
    Aghemo A; Prati GM; Rumi MG; Soffredini R; D'Ambrosio R; Orsi E; De Nicola S; Degasperi E; Grancini V; Colombo M
    Hepatology; 2012 Nov; 56(5):1681-7. PubMed ID: 22619107
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
    Payan C; Pivert A; Morand P; Fafi-Kremer S; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F;
    Gut; 2007 Aug; 56(8):1111-6. PubMed ID: 17363475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.